Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1 Multicenter Study Evaluating the Safety and Efficacy of ALLO-316 Following ALLO-647 Containing Conditioning Regimen in Subjects With Advanced or Metastatic Clear Cell Renal Cell Carcinoma

Next Previous
Trial Profile

A Phase 1 Multicenter Study Evaluating the Safety and Efficacy of ALLO-316 Following ALLO-647 Containing Conditioning Regimen in Subjects With Advanced or Metastatic Clear Cell Renal Cell Carcinoma

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 08 Jun 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs ALLO 647 (Primary) ; ALLO-316 (Primary) ; Cyclophosphamide; Fludarabine
  • Indications Renal cell carcinoma
  • Focus Adverse reactions; First in man; Proof of concept
  • Acronyms TRAVERSE
  • Sponsors Allogene Therapeutics

Most Recent Events

  • 01 Jun 2025 Results presented in an Allogene Therapeutics media release
  • 01 Jun 2025 According to an Allogene Therapeutics media release, updated data from the Phase 1 TRAVERSE study of ALLO-316 was presented in renal cell carcinoma (RCC) during an oral presentation at the 2025 ASCO Annual Meeting.
  • 23 Apr 2025 According to an Allogene Therapeutics media release, the updated results from this study will be presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 29-June 2 in Chicago, Illinois.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top